XML 85 R73.htm IDEA: XBRL DOCUMENT v3.10.0.1

Commitments and Contingencies - Additional Information (Detail) € in Millions, $ in Millions, $ in Millions					1 Months Ended									3 Months Ended	6 Months Ended	9 Months Ended
	Oct. 04, 2018 USD ($)	Jun. 27, 2018 CAD ($)	Aug. 21, 2017 USD ($)	Jul. 15, 2015 USD ($)	Jun. 30, 2018 USD ($)	Nov. 30, 2017 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2013 USD ($)	Aug. 31, 2012 USD ($)	Dec. 31, 2010 USD ($)	Nov. 30, 2009 USD ($)	Aug. 31, 2008 USD ($)	Apr. 30, 2005 USD ($)	Mar. 31, 2015 CAD ($)	Jun. 30, 2018 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2018 EUR (€)	Sep. 30, 2018 CAD ($)	Jun. 20, 2017 USD ($)	Dec. 31, 2016 USD ($)	May 31, 2015 USD ($)	Mar. 31, 2014 USD ($)	Nov. 30, 2013 USD ($)	Aug. 31, 2013 USD ($)	Jan. 31, 2009 USD ($)	Jul. 31, 2008 USD ($)	Feb. 28, 2005 USD ($)
Commitment And Contingencies [Line Items]
Damages assessment																			$ 235.5
Sales														$ 94
Brand sales						$ 459.0
Modafinil payment																					$ 1,200.0
Modafinil Euro sales | €																	€ 46.5
Annual sales at the time of settlement																									$ 350.0
Annual sales of Effexor			$ 2,600.0
Annual sales of Lamictal																										$ 2,300.0	$ 950.0
Annual sales of Niaspan								$ 1,100.0					$ 416.0
Annual sales of Lidoderm								$ 1,400.0															$ 1,200.0
Annual sales of Aggrenox				$ 455.0								$ 340.0
Annual sales of Actos									$ 2,800.0	$ 3,700.0
Annual sales of Acto plus									$ 430.0	$ 500.0
Nexium settlement payment							$ 24.0
Annual sales of Namenda											$ 1,100.0				$ 1,400.0
Annual sales of Intuniv							$ 327.0													$ 335.0
Compensatory Damages And Penalties																								$ 12.4
Punitive Damages																						$ 17.9
Eosinophilic Esophagitis [Member]
Commitment And Contingencies [Line Items]
Damage claimed																$ 200.0
Israel [Member]
Commitment And Contingencies [Line Items]
Loss contingency payment																22.0
United States [Member] | Eosinophilic Esophagitis [Member]
Commitment And Contingencies [Line Items]
Damage claimed																150.0
Europe [Member] | Eosinophilic Esophagitis [Member]
Commitment And Contingencies [Line Items]
Damage claimed																50.0
Subsequent Event [Member]
Commitment And Contingencies [Line Items]
Litigation settlement amount	$ 135.0
AndroGel Rate at 1% [Member]
Commitment And Contingencies [Line Items]
Annual sales at the time of settlement																									140.0
AndroGel Rate at 1.62% [Member]
Commitment And Contingencies [Line Items]
Annual sales at the time of settlement																									$ 1,050.0
AbbVie [Member]
Commitment And Contingencies [Line Items]
Litigation settlement awarded from other party					$ 448.0
Janssen and Millennium [Member]
Commitment And Contingencies [Line Items]
Maximum damages payable																$ 159.0		$ 200
Litigation settlement awarded from other party		$ 5

X

- Definition

Annual sales at time of settlement.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesAtTimeOfSettlement
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Annual sales of Acto plus.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfActoplus
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Annual sales of Actos.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfActos
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Annual sales of Aggrenox.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfAggrenox
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Annual sales of effexor.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfEffexor
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Annual sales of Intuniv.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfIntuniv
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Annual sales of Lamictal.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfLamictal
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Annual sales of Lidoderm.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfLidoderm
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Annual sales of Namenda.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfNamenda
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Annual sales of Niaspan.

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfNiaspan
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Annual Sales Of Velcade

+ References

No definition available.

+ Details

Name:	teva_AnnualSalesOfVelcade
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Brand sales of palonosetron IV product.

+ References

No definition available.

+ Details

Name:	teva_BrandSalesOfPalonosetronIvProduct
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Commitment And Contingencies [Line Items]

+ References

No definition available.

+ Details

Name:	teva_CommitmentAndContingenciesLineItems
Namespace Prefix:	teva_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Compensatory damages and penalties.

+ References

No definition available.

+ Details

Name:	teva_CompensatoryDamagesAndPenalties
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Damages assessment.

+ References

No definition available.

+ Details

Name:	teva_DamagesAssessment
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Modafinil Euro sales.

+ References

No definition available.

+ Details

Name:	teva_ModafinilEuroSales
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

X

- Definition

Modafinil payment.

+ References

No definition available.

+ Details

Name:	teva_ModafinilPayment
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Nexium settlement payment.

+ References

No definition available.

+ Details

Name:	teva_NexiumSettlementPayment
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Punitive damages.

+ References

No definition available.

+ Details

Name:	teva_PunitiveDamages
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount awarded from other party in judgment or settlement of litigation.

+ References

No definition available.

+ Details

Name:	us-gaap_LitigationSettlementAmountAwardedFromOtherParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Amount awarded to other party in judgment or settlement of litigation.

+ References

No definition available.

+ Details

Name:	us-gaap_LitigationSettlementAmountAwardedToOtherParty
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of damages paid to the plaintiff in the legal matter.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349

+ Details

Name:	us-gaap_LossContingencyDamagesPaidValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

The value (monetary amount) of the award the plaintiff seeks in the legal matter.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14326-108349

+ Details

Name:	us-gaap_LossContingencyDamagesSoughtValue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14435-108349

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 9
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=82911808&loc=d3e14557-108349

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=115931803&loc=d3e12021-110248

+ Details

Name:	us-gaap_LossContingencyEstimateOfPossibleLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=teva_EosinophilicEsophagitisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=country_IL
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePercentageMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=teva_AndroGelRateAtOnePointSixTwoPercentageMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=teva_AbbVieMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_CounterpartyNameAxis=teva_JanssenAndMillenniumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: